bpc-157 side effects humans case reports and the Difference Between an Evidence Gap and a Cover-Up: What the entire human evidence base actually looks like, and the questions to ask next. — WellFounded BPC-157 and Healing Peptides: Hype

I ended up in Urgent care and they did all the tests, xrays and found nothing wrong

Dihexa/fosgonimeton is the latest example of this valley of death between preclinical promise and clinical reality

Transcytosis: crossing cellular barriers

50360 Kidney transplant, with unilateral nephrectomy of recipient

While at the 28th day, a diversity of muscle fiber types still persists resulting in different PAS staining (PAS intensity staining + and +++), at 42nd day this diversity vanished, only residual muscle fibers with low PAS intensity staining were observed (Figure 14a,b)

The viability of chemoresistant cells was significantly reduced upon treatment with the MET inhibitor SU11274 [28, 29], MET siRNA [28] or MET shRNA [33] knockdown